Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Authors
Marjolein S. de Bruin-Weller (ORCID: https://orcid.org/0000-0002-1249-6993)
Eric L. Simpson (ORCID: https://orcid.org/0000-0003-0853-0252)
Thomas Bieber (ORCID: https://orcid.org/0000-0002-8800-3817)
Marta Casillas (ORCID: https://orcid.org/0000-0002-6339-5279)
Pablo Fernández‐Peñas (ORCID: https://orcid.org/0000-0003-4882-1564)
Peter Lio (ORCID: https://orcid.org/0000-0001-7600-0152)
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Marjolein S. de Bruin-Weller, Eric L. Simpson, Thomas Bieber, Marta Casillas et al.
Citations
6 citations
Journal
Advances in Therapy
Topics
Dermatology and Skin Diseases
Field-Weighted Citation Impact (FWCI)
3.21
article
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
Marjolein S. de Bruin-Weller, Eric L. Simpson, Thomas Bieber, Marta Casillas, Pablo Fernández‐Peñas, Peter Lio, Yuxin Ding, Chia‐Yu Chu, Khaled Ezzedine, Evangeline Pierce, Helena Agell, Fan Emily Yang
article en
6 citations
Abstract
No abstract available for this paper.
Publication Tag
Advances in TherapyVol. 42(1)
Institutions
Northwestern University (US), The University of Sydney (AU), Oregon Health & Science University (US), Eli Lilly (United States) (US), Utrecht University (NL), Université Paris-Est Créteil (FR), University Hospital Bonn (DE), Westmead Hospital (AU), University Medical Center Utrecht (NL), Almirall (Spain) (ES), National Taiwan University Hospital (TW)